Observational Registry to Assess the Durability of Effect of CXL in Patients With Corneal Ectasia After Refractive Surgery

Approximately 200 patients who are planning to undergo or have undergone CXL for the
treatment of corneal ectasia following refractive surgery in one or both eyes according to
the prescribing information in the Photrexa Viscous and Photrexa Package Insert could be
enrolled. Patients will be followed for safety and effectiveness at Months 3, 6, 12, 24 and
36 following cross-linking treatment.

Inclusion Criteria:

1. Be at least 18 years of age, male or female, of any race;

2. Provide written informed consent and sign a HIPAA form;

3. Willingness and ability to follow all instructions and comply with schedule for study
visits;

4. Have a diagnosis of corneal ectasia post-refractive surgery (such as LASIK, PRK);

5. Planning to undergo (or have undergone within the past 90 days) corneal collagen
cross-linking with PHOTREXA VISCOUS/ PHOTREXA and the KXL System, per the prescribing
information (NOTE: Complete treatment and follow-up data, including any
product-related events at time of procedure through the time of enrollment must be
available);

6. For females capable of becoming pregnant, agree to have urine pregnancy testing
performed prior to enrolling in the registry; must not be pregnant or lactating.

Exclusion Criteria:

1. If female, be pregnant, nursing, or have a positive urine pregnancy test prior to
enrollment in the registry;

2. The Investigator may exclude or discontinue any patient for any sound medical reason.